Complete pathological response after neoadjuvant chemotherapy and the benefit of subsequent surgery in oligometastatic pancreatic cancer patient

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F24%3A73628330" target="_blank" >RIV/61989592:15110/24:73628330 - isvavai.cz</a>

Alternative codes found

RIV/61989592:15120/24:73628330

Result on the web

<a href="https://www.perspinsurg.com/rvch/article/view/1050" target="_blank" >https://www.perspinsurg.com/rvch/article/view/1050</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.48095/ccrvch2024454" target="_blank" >10.48095/ccrvch2024454</a>

Result language

čeština

Original language name

Kompletní patologická odpověď po neoadjuvantní chemoterapii a profit z následné chirurgické léčby u pacienta s oligometastatickým karcinomem pankreatu

Original language description

INTRODUCTION: Pancreatic cancer is one of the most aggressive tumors diagnosed in local-ly advanced or metastatic stage in more than half of the cases. The standard of care is a systemic chemotherapy but the prognosis of metastatic patients remains extremely poor with a median overall survival less than one year.  However, there is increasing evidence of surgery treatment benefit in a carefully selected oligometastatic cases.  -Because oligometastatic pancreatic cancer is rare, there is a lack of robust clinical trials defining strategy, efficacy and safety of this procedure. PATIENT CONCERNS: A 77-year-old man presented with a mass in the tail of the pancreas and solitary liver metastasis. After four cycles of chemotherapy, distal pancreatectomy with liver metastasectomy was performed, and the tissues were histologically examined. The complete pathological response was found in the primary tumor and residual adenocarcinoma in liver metastasis. OUTCOMES: The patient is alive without recurrency more than two years from the diagnosis.

Czech name

Kompletní patologická odpověď po neoadjuvantní chemoterapii a profit z následné chirurgické léčby u pacienta s oligometastatickým karcinomem pankreatu

Czech description

INTRODUCTION: Pancreatic cancer is one of the most aggressive tumors diagnosed in local-ly advanced or metastatic stage in more than half of the cases. The standard of care is a systemic chemotherapy but the prognosis of metastatic patients remains extremely poor with a median overall survival less than one year.  However, there is increasing evidence of surgery treatment benefit in a carefully selected oligometastatic cases.  -Because oligometastatic pancreatic cancer is rare, there is a lack of robust clinical trials defining strategy, efficacy and safety of this procedure. PATIENT CONCERNS: A 77-year-old man presented with a mass in the tail of the pancreas and solitary liver metastasis. After four cycles of chemotherapy, distal pancreatectomy with liver metastasectomy was performed, and the tissues were histologically examined. The complete pathological response was found in the primary tumor and residual adenocarcinoma in liver metastasis. OUTCOMES: The patient is alive without recurrency more than two years from the diagnosis.

Type

J_SC - Article in a specialist periodical, which is included in the SCOPUS database

CEP classification

—

OECD FORD branch

30204 - Oncology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2024

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Rozhledy v chirurgii

ISSN

1805-4579

e-ISSN

0035-9351

Volume of the periodical

103

Issue of the periodical within the volume

11

Country of publishing house

CZ - CZECH REPUBLIC

Number of pages

4

Pages from-to

454-457

UT code for WoS article

—

EID of the result in the Scopus database

2-s2.0-85212033427